Literature DB >> 25802183

Recombinant rubella vectors elicit SIV Gag-specific T cell responses with cytotoxic potential in rhesus macaques.

Margherita Rosati1, Candido Alicea2, Viraj Kulkarni2, Konstantin Virnik3, Max Hockenbury3, Niranjan Y Sardesai4, George N Pavlakis1, Antonio Valentin1, Ira Berkower5, Barbara K Felber6.   

Abstract

Live-attenuated rubella vaccine strain RA27/3 has been demonstrated to be safe and immunogenic in millions of children. The vaccine strain was used to insert SIV gag sequences and the resulting rubella vectors were tested in rhesus macaques alone and together with SIV gag DNA in different vaccine prime-boost combinations. We previously reported that such rubella vectors induce robust and durable SIV-specific humoral immune responses in macaques. Here, we report that recombinant rubella vectors elicit robust de novo SIV-specific cellular immune responses detectable for >10 months even after a single vaccination. The antigen-specific responses induced by the rubella vector include central and effector memory CD4(+) and CD8(+) T cells with cytotoxic potential. Rubella vectors can be administered repeatedly even after vaccination with the rubella vaccine strain RA27/3. Vaccine regimens including rubella vector and SIV gag DNA in different prime-boost combinations resulted in robust long-lasting cellular responses with significant increase of cellular responses upon boost. Rubella vectors provide a potent platform for inducing HIV-specific immunity that can be combined with DNA in a prime-boost regimen to elicit durable cellular immunity. Published by Elsevier Ltd.

Entities:  

Keywords:  CM9 tetramer response; Cytotoxic T cells; DNA prime rubella boost; DNA vaccine; De novo cellular responses; HIV vaccine; IFN-γ response; Live attenuated viral vector; Memory T cells; Recall cellular responses; Rhesus macaque; Rubella prime boost; Rubella vaccine strain RA27/3; SIV Gag

Mesh:

Substances:

Year:  2015        PMID: 25802183      PMCID: PMC7722989          DOI: 10.1016/j.vaccine.2015.02.067

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  49 in total

1.  Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization.

Authors:  Vainav Patel; Antonio Valentin; Viraj Kulkarni; Margherita Rosati; Cristina Bergamaschi; Rashmi Jalah; Candido Alicea; Jacob T Minang; Matthew T Trivett; Claes Ohlen; Jun Zhao; Marjorie Robert-Guroff; Amir S Khan; Ruxandra Draghia-Akli; Barbara K Felber; George N Pavlakis
Journal:  Vaccine       Date:  2010-05-06       Impact factor: 3.641

2.  Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes.

Authors:  Michael A Egan; Siew Yen Chong; Nina F Rose; Shakuntala Megati; Kevin J Lopez; Eva B Schadeck; J Erik Johnson; Amjed Masood; Priscilla Piacente; Robert E Druilhet; Paul W Barras; Dana L Hasselschwert; Patricia Reilly; Eric M Mishkin; David C Montefiori; Mark G Lewis; David K Clarke; R Michael Hendry; Preston A Marx; John H Eldridge; Stephen A Udem; Zimra R Israel; John K Rose
Journal:  AIDS Res Hum Retroviruses       Date:  2004-09       Impact factor: 2.205

3.  Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses.

Authors:  Nina V Malkevitch; L Jean Patterson; M Kristine Aldrich; Yichen Wu; David Venzon; Ruth H Florese; V S Kalyanaraman; Ranajit Pal; Eun Mi Lee; Jun Zhao; Anthony Cristillo; Marjorie Robert-Guroff
Journal:  Virology       Date:  2006-06-30       Impact factor: 3.616

4.  Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope.

Authors:  K Haglund; J Forman; H G Kräusslich; J K Rose
Journal:  Virology       Date:  2000-03-01       Impact factor: 3.616

5.  A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes.

Authors:  Clarisse Lorin; Frédéric Delebecque; Valérie Labrousse; Lucie Da Silva; François Lemonnier; Michel Brahic; Frédéric Tangy
Journal:  Vaccine       Date:  2005-08-22       Impact factor: 3.641

Review 6.  Live, attenuated rubella-virus vaccine.

Authors:  M R Hilleman; E B Buynak; R E Weibel; J Stokes
Journal:  N Engl J Med       Date:  1968-08-08       Impact factor: 91.245

7.  Rubella vaccine.

Authors:  S A Plotkin
Journal:  J Infect Dis       Date:  1995-06       Impact factor: 5.226

8.  Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes.

Authors:  Kaifan Dai; Ying Liu; Mingjie Liu; Jianqing Xu; Wei Huang; Xianggang Huang; Lianxing Liu; Yanmin Wan; Yanling Hao; Yiming Shao
Journal:  Vaccine       Date:  2008-06-23       Impact factor: 3.641

9.  HIV-1 conserved elements p24CE DNA vaccine induces humoral immune responses with broad epitope recognition in macaques.

Authors:  Viraj Kulkarni; Antonio Valentin; Margherita Rosati; Morgane Rolland; James I Mullins; George N Pavlakis; Barbara K Felber
Journal:  PLoS One       Date:  2014-10-22       Impact factor: 3.240

10.  A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV.

Authors:  Clarisse Lorin; Lucile Mollet; Frédéric Delebecque; Chantal Combredet; Bruno Hurtrel; Pierre Charneau; Michel Brahic; Frédéric Tangy
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

View more
  4 in total

Review 1.  New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.

Authors:  Thomas Musich; Marjorie Robert-Guroff
Journal:  Expert Rev Vaccines       Date:  2016-03-16       Impact factor: 5.217

2.  DNA Prime-Boost Vaccine Regimen To Increase Breadth, Magnitude, and Cytotoxicity of the Cellular Immune Responses to Subdominant Gag Epitopes of Simian Immunodeficiency Virus and HIV.

Authors:  Xintao Hu; Antonio Valentin; Frances Dayton; Viraj Kulkarni; Candido Alicea; Margherita Rosati; Bhabadeb Chowdhury; Rajeev Gautam; Kate E Broderick; Niranjan Y Sardesai; Malcolm A Martin; James I Mullins; George N Pavlakis; Barbara K Felber
Journal:  J Immunol       Date:  2016-10-12       Impact factor: 5.422

Review 3.  T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.

Authors:  Anne Monette; Andrew J Mouland
Journal:  Int Rev Cell Mol Biol       Date:  2018-10-24       Impact factor: 6.813

4.  Immunotherapy with DNA vaccine and live attenuated rubella/SIV gag vectors plus early ART can prevent SIVmac251 viral rebound in acutely infected rhesus macaques.

Authors:  Konstantin Virnik; Margherita Rosati; Alexei Medvedev; Aaron Scanlan; Gabrielle Walsh; Frances Dayton; Kate E Broderick; Mark Lewis; Yvonne Bryson; Jeffrey D Lifson; Ruth M Ruprecht; Barbara K Felber; Ira Berkower
Journal:  PLoS One       Date:  2020-03-04       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.